Matching articles for "Tenofovir"
Issue 1579 · August 26, 2019
Dolutegravir/Lamivudine (Dovato) - A Two-Drug Complete Regimen for HIV-1 Infection

The FDA has approved Dovato (ViiV), a fixed-dose combination of the integrase strand transfer inhibitor (INSTI) dolutegravir (Tivicay) and the nucleoside reverse transcriptase inhibitor (NRTI) lamivudine (…

Med Lett Drugs Ther. 2019 Aug 26; 61(1579):134-6
The FDA has approved Dovato (ViiV), a fixed-dose combination of the integrase strand transfer inhibitor (INSTI) dolutegravir (Tivicay) and the nucleoside reverse transcriptase inhibitor (NRTI) lamivudine ( Epivir , and generics), as a once-daily complete regimen for treatment of adults with HIV-1 infection who are antiretroviral-treatment naive and have no known substitutions associated with resistance to either drug. Dolutegravir/lamivudine is the first complete regimen to be approved by the FDA for initial treatment of HIV-1 infection that contains 2 rather than 3 antiretroviral drugs. Juluca , a fixed-dose combination of dolutegravir and the non-nucleoside reverse transcriptase inhibitor (NNRTI) rilpivirine (Edurant) , was approved in 2018 for treatment of adults with HIV-1 infection already taking a stable, suppressive antiretroviral regimen.
Issue 1563 · January 14, 2019
Symfi, Symfi Lo, and Cimduo for HIV (online only)

The FDA has approved three new once-daily fixed-dose antiretroviral drug combinations for treatment of HIV-1 infection. Symfi and Symfi Lo (Mylan) contain the non-nucleoside reverse transcriptase inhibitor…

Med Lett Drugs Ther. 2019 Jan 14; 61(1563):e8-10
The FDA has approved three new once-daily fixed-dose antiretroviral drug combinations for treatment of HIV-1 infection. Symfi and Symfi Lo (Mylan) contain the non-nucleoside reverse transcriptase inhibitor (NNRTI) efavirenz and the nucleoside reverse transcriptase inhibitors (NRTIs) lamivudine and tenofovir disoproxil fumarate (TDF) and were approved as complete antiretroviral regimens. Symfi Lo contains a lower dose of efavirenz than both Symfi and Atripla , a fixed-dose combination of efavirenz, TDF, and the NRTI emtricitabine that was approved in 2006. Cimduo (Mylan), which contains lamivudine and TDF, was approved for use in combination with other antiretroviral drugs. All three new products are marketed as less expensive alternatives to other available fixed-dose antiretroviral combinations (see Table 1).
Issue 1561 · December 3, 2018
Juluca - A Two-Drug Complete Regimen for HIV (online only)

The FDA has approved Juluca (ViiV Healthcare/Janssen), a fixed-dose combination of the integrase strand transfer inhibitor (INSTI) dolutegravir (Tivicay) and the non-nucleoside reverse transcriptase inhibitor…

Med Lett Drugs Ther. 2018 Dec 3; 60(1561):e202-4
The FDA has approved Juluca (ViiV Healthcare/Janssen), a fixed-dose combination of the integrase strand transfer inhibitor (INSTI) dolutegravir (Tivicay) and the non-nucleoside reverse transcriptase inhibitor (NNRTI) rilpivirine (Edurant ), as a once-daily complete regimen for treatment of adults with HIV-1 infection who do not have a history of treatment failure or known substitutions associated with resistance to either drug and have been taking a stable suppressive antiretroviral regimen for ≥6 months. Dolutegravir/rilpivirine is the first complete regimen to be approved for treatment of HIV-1 infection that contains 2 rather than 3 antiretroviral drugs and the first that does not include a nucleoside reverse transcriptase inhibitor (NRTI).
Issue 1511 · January 2, 2017
Tenofovir Alafenamide (Vemlidy) for Hepatitis B

The FDA has approved tenofovir alafenamide ( Vemlidy – Gilead) for treatment of chronic hepatitis B virus (HBV) infection in adults with compensated liver disease. It is the first single-drug product…

Med Lett Drugs Ther. 2017 Jan 2; 59(1511):6-8
The FDA has approved tenofovir alafenamide ( Vemlidy – Gilead) for treatment of chronic hepatitis B virus (HBV) infection in adults with compensated liver disease. It is the first single-drug product containing tenofovir alafenamide (TAF), a prodrug of the nucleotide reverse transcriptase inhibitor tenofovir, to become available; several combination products containing TAF are approved for treatment of HIV-1 infection. Tenofovir disoproxil fumarate (TDF; Viread – Gilead), another tenofovir prodrug, has been used for many years for treatment of chronic HBV infection; a generic formulation of TDF is expected to become available in December 2017.
Issue 1494 · May 9, 2016
Odefsey - Another NNRTI Combination for HIV

The FDA has approved Odefsey (Gilead), a once-daily, fixed-dose combination of the non-nucleoside reverse transcriptase inhibitor (NNRTI) rilpivirine and the nucleoside/nucleotide reverse transcriptase…

Med Lett Drugs Ther. 2016 May 9; 58(1494):60-1
The FDA has approved Odefsey (Gilead), a once-daily, fixed-dose combination of the non-nucleoside reverse transcriptase inhibitor (NNRTI) rilpivirine and the nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs) emtricitabine and tenofovir alafenamide, for initial treatment of HIV-1 infection in patients with HIV-1 RNA (viral load) ≤100,000 copies/mL or to replace a stable antiretroviral regimen in patients who have been virologically suppressed (viral load <50 copies/mL) for at least six months with no history of treatment failure.
Issue 1488 · February 15, 2016
Genvoya - A New 4-Drug Combination for HIV

The FDA has approved Genvoya (Gilead), a fixed-dose combination of the integrase strand transfer inhibitor (INSTI) elvitegravir, the pharmacokinetic enhancer cobicistat, and the nucleoside/nucleotide reverse…

Med Lett Drugs Ther. 2016 Feb 15; 58(1488):19-21
The FDA has approved Genvoya (Gilead), a fixed-dose combination of the integrase strand transfer inhibitor (INSTI) elvitegravir, the pharmacokinetic enhancer cobicistat, and the nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs) emtricitabine and tenofovir alafenamide, for treatment of HIV-1 infection in patients ≥12 years old. This is the first approval for tenofovir alafenamide (TAF), a tenofovir prodrug. Stribild , a fixed-dose combination of elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate (TDF), was approved in 2012.
Issue 1482 · November 23, 2015
Cobicistat (Tybost) and Combinations for HIV

Cobicistat, a pharmacokinetic enhancer that boosts levels of some HIV drugs but has no antiretroviral activity of its own, is now available alone as Tybost (Gilead) and in fixed-dose combinations with the…

Med Lett Drugs Ther. 2015 Nov 23; 57(1482):159-60
Cobicistat, a pharmacokinetic enhancer that boosts levels of some HIV drugs but has no antiretroviral activity of its own, is now available alone as Tybost (Gilead) and in fixed-dose combinations with the protease inhibitors atazanavir ( Evotaz — BMS) and darunavir ( Prezcobix — Janssen) for treatment of HIV-1 infection. Both atazanavir and darunavir have traditionally been used in combination with the CYP3A inhibitor ritonavir (Norvir) to boost their serum concentrations, but neither is available in a fixed-dose combination with ritonavir.
Issue 1459 · January 5, 2015
Triumeq: A 3-Drug Combination for HIV

The FDA has approved Triumeq (Viiv Healthcare), a fixed-dose combination of the integrase strand transfer inhibitor (INSTI) dolutegravir and the nucleoside reverse transcriptase inhibitors (NRTIs) abacavir and…

Med Lett Drugs Ther. 2015 Jan 5; 57(1459):7-8
The FDA has approved Triumeq (Viiv Healthcare), a fixed-dose combination of the integrase strand transfer inhibitor (INSTI) dolutegravir and the nucleoside reverse transcriptase inhibitors (NRTIs) abacavir and lamivudine, for once-daily treatment of HIV-1 infection. Dolutegravir (Tivicay) was approved as a single agent in 2013.
Issue 1455 · November 10, 2014
A Combination of Ledipasvir and Sofosbuvir (Harvoni) for Hepatitis C

The FDA has approved a fixed-dose combination ( Harvoni [har voe' nee] – Gilead) of sofosbuvir and ledipasvir (led' i pas' vir), two oral direct-acting antiviral agents, for treatment of chronic hepatitis C…

Med Lett Drugs Ther. 2014 Nov 10; 56(1455):111-2
The FDA has approved a fixed-dose combination ( Harvoni [har voe' nee] – Gilead) of sofosbuvir and ledipasvir (led' i pas' vir), two oral direct-acting antiviral agents, for treatment of chronic hepatitis C virus (HCV) genotype 1 infection. Genotype 1 is responsible for 70-80% of HCV infections in the US. Sofosbuvir (Sovaldi) was approved earlier for use in combination with other antiviral drugs for treatment of HCV infection. Ledipasvir is a new drug.
Issue 138 · February 1, 2014
Drugs for HIV Infection

Antiretroviral therapy is recommended for all HIV-infected patients, both to reduce the risk of disease progression and to prevent transmission of the virus to others. Various guidelines for treatment of HIV…

Treat Guidel Med Lett. 2014 Feb; 12(138):7-16
Antiretroviral therapy is recommended for all HIV-infected patients, both to reduce the risk of disease progression and to prevent transmission of the virus to others. Various guidelines for treatment of HIV infection are available.
Issue 1426 · September 30, 2013
Dolutegravir (Tivicay) for HIV

The FDA has approved dolutegravir (doll-you-TEG-rah-veer; Tivicay – Viiv Healthcare), an integrase strand transfer inhibitor (INSTI), for treatment of HIV-1 infection in adults and in children ≥12 years…

Med Lett Drugs Ther. 2013 Sep 30; 55(1426):77-9
The FDA has approved dolutegravir (doll-you-TEG-rah-veer; Tivicay – Viiv Healthcare), an integrase strand transfer inhibitor (INSTI), for treatment of HIV-1 infection in adults and in children ≥12 years old who weigh at least 40 kg. It is the third INSTI to be approved by the FDA; raltegravir and elvitegravir were approved earlier.
Issue 127 · March 1, 2013
Antiviral Drugs

The drugs of choice for treatment of viral infections (other than HIV) and their dosages are listed in Tables 1-6 on the pages that follow. Some of the indications and dosages recommended here have not been…

Treat Guidel Med Lett. 2013 Mar; 11(127):19-30
The drugs of choice for treatment of viral infections (other than HIV) and their dosages are listed in Tables 1-6 on the pages that follow. Some of the indications and dosages recommended here have not been approved by the FDA. Vaccines used for the prevention of viral infections are discussed elsewhere.
Issue 1404 · November 26, 2012
A 4-Drug Combination (Stribild) for HIV

The FDA has approved a fixed-dose combination of the integrase strand transfer inhibitor (INSTI) elvitegravir, the pharmacokinetic enhancer cobicistat, and the nucleoside/nucleotide reverse transcriptase…

Med Lett Drugs Ther. 2012 Nov 26; 54(1404):95-6
The FDA has approved a fixed-dose combination of the integrase strand transfer inhibitor (INSTI) elvitegravir, the pharmacokinetic enhancer cobicistat, and the nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs) emtricitabine and tenofovir disoproxil fumarate ( Stribild – Gilead) for treatment of HIV-1 infection in antiretroviral treament-naïve adults. Elvitegravir is the second INSTI to be approved by the FDA for use in HIV treatment; raltegravir (Isentress) was the first.
Issue 1396 · August 6, 2012 Free
In Brief: Truvada for HIV Prevention

Truvada (Gilead), an oral fixed-dose combination of the antiretrovirals emtricitabine and tenofovir disoproxil fumarate frequently used for treatment of HIV infection, 1 has now also been approved by the FDA…

Med Lett Drugs Ther. 2012 Aug 6; 54(1396):63-4
Truvada (Gilead), an oral fixed-dose combination of the antiretrovirals emtricitabine and tenofovir disoproxil fumarate frequently used for treatment of HIV infection, 1 has now also been approved by the FDA for pre-exposure prophylaxis to reduce the risk of sexually acquired HIV-1 in adults at high risk. It is the first drug to be approved for this indication. The CDC has been recommending Truvada off-label for pre-exposure prophylaxis in men who have sex with men since 2011. 2 A 30-day supply of Truvada costs about $1160. 3 CLINICAL STUDIES — Approval for the new indication was based on 2 randomized, placebo-controlled trials in high-risk patients. One trial in 2,499 HIV-negative men (or transgender women) who have sex with men found that daily use of the combination reduced the risk of HIV seroconversion by 44% (36 seroconversions vs. 64 with placebo). 4 A post-hoc analysis found that the rate of infection was reduced by 87.5% compared to placebo among men found to be adherent to the drug regimen (i.e., had detectable intracellular tenofovir levels). 5 The second trial included 4,747 heterosexual couples among whom one partner was HIV-infected and the other was not. Truvada reduced the risk of becoming infected by 75% (13 seroconversions vs. 52 with placebo). 6 RECOMMENDATIONS — Pre-exposure prophylaxis with Truvada should be considered only for persons who are at high risk for HIV-1 acquisition, are confirmed to be HIV-negative and are willing to take the drug once daily and practice safer sex. Frequent follow-up HIV antibody testing is recommended while taking the drug to ensure early diagnosis of newly-acquired HIV infection; resistance to tenofovir/emtricitabine can develop if it is taken prophylactically by patients with HIV infection. 1. Drugs for HIV infection. Treat Guidel Med Lett 2011; 9:29. 2. Centers for Disease Control and Prevention (CDC). Interim guidance: preexposure prophylaxis for the prevention of HIV infection in men who have sex with men. MMWR Morb Mortal Wkly Rep 2011; 60:65. 3. Wholesale acquisition cost (WAC). Source: PricePointRx™. Reprinted with permission by FDB. All rights reserved. ©2012. http://www.firstdatabank.com/support/drug-pricing-policy.aspx. Accessed July 25, 2012. Actual retail price may be higher. 4. RM Grant et al. Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med 2010; 363:2587. 5. FDA. Background package for NDA 21-752/supplement 30. Available at: http://www.fda.gov/downloads/AdvisoryCommittees/CommitteeMeetingMaterials/Drugs/AntiviralDrugsAdvisoryCommittee/UCM303213.pdf. Accessed July 25, 2012. 6. JM Baeten et al. Antiretroviral prophylaxis for HIV prevention in heterosexual men and women. N Engl J Med 2012 Jul 11 (epub). Download complete U.S. English article
Issue 1371 · August 22, 2011
Rilpivirine (Edurant) - A New Drug for HIV Infection

The FDA has approved rilpivirine ( Edurant – Janssen), a non-nucleoside reverse transcriptase inhibitor (NNRTI), for use with other antiretroviral agents for treatment of HIV-1 infection in treatment-naive…

Med Lett Drugs Ther. 2011 Aug 22; 53(1371):67-8
The FDA has approved rilpivirine ( Edurant – Janssen), a non-nucleoside reverse transcriptase inhibitor (NNRTI), for use with other antiretroviral agents for treatment of HIV-1 infection in treatment-naive adults. Rilpivirine is also available in a fixed-dose combination with emtricitabine and tenofovir ( Complera – Gilead).
Issue 106 · June 1, 2011
Drugs for HIV Infection

Guidelines for use of antiretroviral agents continue to shift toward earlier and more continuous treatment, both to treat the patient and to prevent transmission of the disease to others. Resistance testing is…

Treat Guidel Med Lett. 2011 Jun; 9(106):29-40
Guidelines for use of antiretroviral agents continue to shift toward earlier and more continuous treatment, both to treat the patient and to prevent transmission of the disease to others. Resistance testing is now recommended when antiretroviral drugs are started. Increases in HIV RNA levels ("viral load") while on therapy may indicate development of drug resistance, requiring further testing and a change in the treatment regimen. Antiretroviral drugs interact with each other and with many other drugs; complete information on these interactions is available at www.aidsinfo.nih.gov .
Issue 98 · October 1, 2010
Drugs for Non-HIV Viral Infections

The drugs of choice for treatment of non-HIV viral infections and their dosages are listed in Tables 1-6 on the pages that follow. Some of the indications and dosages recommended here have not been approved by…

Treat Guidel Med Lett. 2010 Oct; 8(98):71-82
The drugs of choice for treatment of non-HIV viral infections and their dosages are listed in Tables 1-6 on the pages that follow. Some of the indications and dosages recommended here have not been approved by the FDA. Vaccines used for the prevention of viral infections are discussed in another issue of Treatment Guidelines .
Issue 78 · February 1, 2009
Drugs for HIV Infection

New guidelines for use of antiretroviral agents have been published, with a shift towards earlier and more continuous treatment. HIV infection is treated with combinations of antiretroviral drugs depending on…

Treat Guidel Med Lett. 2009 Feb; 7(78):11-22
New guidelines for use of antiretroviral agents have been published, with a shift towards earlier and more continuous treatment. HIV infection is treated with combinations of antiretroviral drugs depending on the patientÆs HIV RNA levels ("viral load") and CD4 cell count. Increases in viral load while on therapy may indicate development of drug resistance, requiring further testing and a change in treatment regimen. Resistance testing is now recommended when a patient is first seen, regardless of when therapy will be started.
Issue 50 · October 1, 2006
Drugs for HIV Infection

The approval of new drugs and continuing concerns about drug toxicity and resistance have prompted new antiretroviral treatment guidelines. Resistance testing is not recommended before starting antiretroviral…

Treat Guidel Med Lett. 2006 Oct; 4(50):67-76
The approval of new drugs and continuing concerns about drug toxicity and resistance have prompted new antiretroviral treatment guidelines. Resistance testing is not recommended before starting antiretroviral therapy. HIV infection is treated with combinations of antiretroviral drugs while monitoring the patient's HIV RNA levels ("viral load") and CD4 cell count. Increases in viral load while on therapy may indicate development of drug resistance requiring further testing and a change in treatment regimen.
Issue 1203 · February 28, 2005
Two Once-Daily Fixed-Dose NRTI Combinations for HIV

The FDA has approved emtricitabine/tenofovir ( Truvada - Gilead) and abacavir/lamivudine ( Epzicom - GSK), two new fixed-dose combinations of nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs), for…

Med Lett Drugs Ther. 2005 Feb 28; 47(1203):19-20
The FDA has approved emtricitabine/tenofovir ( Truvada - Gilead) and abacavir/lamivudine ( Epzicom - GSK), two new fixed-dose combinations of nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs), for once-daily use in treatment of HIV infection. Two other fixed-dose NRTI combinations were previously approved for twice-daily dosing. Dual NRTI therapy is generally used in either an NNRTI (non-nucleoside reverse transcriptase inhibitor)-based or a PI (protease inhibitor)-based regimen.
Issue 17 · January 1, 2004
Drugs for HIV

New drug approvals as well as continuing concerns about drug toxicity and the development of resistance have prompted new antiretroviral treatment guidelines (Panel on Clinical Practices for Treatment of HIV…

Treat Guidel Med Lett. 2004 Jan; 2(17):1-6
New drug approvals as well as continuing concerns about drug toxicity and the development of resistance have prompted new antiretroviral treatment guidelines (Panel on Clinical Practices for Treatment of HIV Infection, November 10, 2003, www.aidsinfo.nih.gov ).
Issue 1169 · November 10, 2003
Atazanavir (Reyataz) and Emtricitabine (Emtriva) for HIV Infection

Atazanavir ( Reyataz - Bristol-Myers Squibb), a new protease inhibitor (PI), and emtricitabine ( Emtriva - Gilead), a nucleoside analogue reverse transcriptase inhibitor (NRTI) chemically similar to…

Med Lett Drugs Ther. 2003 Nov 10; 45(1169):90-2
Atazanavir ( Reyataz - Bristol-Myers Squibb), a new protease inhibitor (PI), and emtricitabine ( Emtriva - Gilead), a nucleoside analogue reverse transcriptase inhibitor (NRTI) chemically similar to lamivudine, have been approved by the FDA for treatment of HIV-1 infection. Both are taken once daily, unlike most anti-HIV drugs.
Issue 1119 · November 26, 2001
Drugs for HIV

Since the last Medical Letter article on this subject, continuing concerns about drug toxicity and development of resistance have prompted new antiretroviral treatment guidelines. The dosage and cost of drugs…

Med Lett Drugs Ther. 2001 Nov 26; 43(1119):103-8
Since the last Medical Letter article on this subject, continuing concerns about drug toxicity and development of resistance have prompted new antiretroviral treatment guidelines. The dosage and cost of drugs for HIV infection are listed in the table in this article.